Development of dengue virus vaccine components

US9090873B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Stephen S. Whitehead · Montgomery Village, US
• Joseph E. Blaney · Frederick, US
• Brian R. Murphy · Bethesda, US
• Ching-Juh Lai · Bethesda, US

Key dates

• Filing date: Dec 3, 2012
• Grant date: Jul 28, 2015
• Expiry date: Feb 17, 2033

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′direction as far as the 5′boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.